Pharma Two B

Pharma Two B is a clinical-stage pharmaceutical company developing novel, synergistic combination products based on previously approved drugs. We have refined years of expertise to identify and characterize potential drug combinations that can deliver high therapeutic efficacy and improved safety. Our goal is to develop combination products with clinical significance, safety, and commercial added value through the US 505(b)(2) regulatory pathway to address unmet medical needs and shortened FDA approval times. Our lead product, P2B001, is being studied as a once-daily treatment for early Parkinson's disease (PD) that does not require titration.